Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Seongmin | - |
dc.contributor.author | Jang, Nawon | - |
dc.contributor.author | Kim, Minchae | - |
dc.contributor.author | Choi, Il-Kyu | - |
dc.date.accessioned | 2023-07-12T11:40:20Z | - |
dc.date.available | 2023-07-12T11:40:20Z | - |
dc.date.created | 2023-04-04 | - |
dc.date.issued | 2023-02 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11750/46130 | - |
dc.description.abstract | While CD8+ cytotoxic T cells have long been considered the primary effector in controlling tumors, the involvement of CD4+ “helper” T cells in anti-tumor immunity has been underappreciated. The investigations of intra-tumoral T cells, fueled by the recent advances in genomic technologies, have led to a rethinking of the indirect role of CD4+ T cells that have traditionally been described as a “helper”. Accumulating evidence from preclinical and clinical studies indicates that CD4+ T cells can acquire intrinsic cytotoxic properties and directly kill various types of tumor cells in a major histocompatibility complex class II (MHC-II)-dependent manner, as opposed to the indirect “helper” function, thus underscoring a potentially critical contribution of CD4+ cytotoxic T cells to immune responses against a wide range of tumor types. Here, we discuss the biological properties of anti-tumor CD4+ T cells with cytotoxic capability and highlight the emerging observations suggesting their more significant role in anti-tumor immunity than previously appreciated. © 2023 by the The Korean Society for Biochemistry and Molecular Biology | - |
dc.language | English | - |
dc.publisher | 생화학분자생물학회 | - |
dc.title | CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity | - |
dc.type | Article | - |
dc.identifier.doi | 10.5483/BMBRep.2023-0014 | - |
dc.identifier.scopusid | 2-s2.0-85151044432 | - |
dc.identifier.bibliographicCitation | BMB Reports, v.56, no.3, pp.140 - 144 | - |
dc.identifier.kciid | ART002943797 | - |
dc.description.isOpenAccess | FALSE | - |
dc.subject.keywordAuthor | Anti-tumor immunity | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | CD4+ cytotoxic T cells | - |
dc.subject.keywordAuthor | CD4+ “helper” T cells | - |
dc.subject.keywordAuthor | MHC-II antigen presentation | - |
dc.subject.keywordPlus | HLA CLASS-II | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | LANDSCAPE | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.citation.endPage | 144 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 140 | - |
dc.citation.title | BMB Reports | - |
dc.citation.volume | 56 | - |
There are no files associated with this item.